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(PARP-1) Binding to the NACP-Rep1 Polymorphic Site Upstream of the
SNCA Gene
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Alleles at NACP-Rep1, the polymorphic microsatellite repeat located ∼10 kb upstream of the a-synuclein gene
(SNCA), are associated, in some reports, with differing risks of sporadic Parkinson disease (PD). We showed
previously that NACP-Rep1 acts as a negative modulator of SNCA transcription, with an effect that varied threefold
among different NACP-Rep1 alleles. Given that duplications and triplications of SNCA have been implicated in
familial Parkinson disease (PD), even a 1.5–2-fold increase in a-synuclein expression may, over many decades,
contribute to PD. Thus, the association of different NACP-Rep1 alleles with PD may be a consequence of poly-
morphic differences in transcriptional regulation of SNCA. Here we aimed to identify the factor(s) that bind to
NACP-Rep1 and potentially contribute to SNCA transcriptional modulation, by pulling down proteins that bind
to NACP-Rep1 and identifying them by mass spectrometry. One of these proteins was poly-(ADP-ribose) transferase/
polymerase-1 (PARP-1), a DNA-binding protein and transcriptional regulator. Electrophoresis mobility shift and
chromatin immunoprecipitation assays showed specific binding of PARP-1 to NACP-Rep1. Inhibition of PARP-1’s
catalytic domain increased the endogenous SNCA mRNA levels in cultured SH-SY5Y cells. Furthermore, PARP-1
binding to NACP-Rep1 specifically reduced the transcriptional activity of the SNCA promoter/enhancer in luciferase
reporter assays. This down-regulation effect of PARP-1 depended on NACP-Rep1 being present in the construct
and was abrogated by inhibiting PARP-1’s catalytic activity with 3-aminobenzamide. The association of different
NACP-Rep1 alleles with PD may be mediated, in part, by the effect of PARP-1, as well as other factors, on SNCA
expression.
Introduction
Parkinson disease (PD) (MIM 168600) is the second
most common neurodegenerative disease in humans; its
etiology is largely unknown. SNCA (MIM 163890), the
gene encoding the presynaptic protein a-synuclein, was
the first gene in which mutations were found to cause
PD. Three missense mutations in the SNCA gene have
been shown to cause an early-onset, autosomal domi-
nant PD with, in some families, Lewy body pathology
at autopsy (Polymeropoulos et al. 1997; Kruger et al.
1998; Zarranz et al. 2004). Recently, Singleton et al.
(2003) reported a genomic triplication of the region con-
taining a-synuclein in affected individuals of another
kindred, in which PD presented as an autosomal dom-
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inant disease. This triplication resulted in four fully func-
tional copies of SNCA and twofold overexpression of
a-synuclein mRNA and protein (Farrer et al. 2004; Mil-
ler et al. 2004). Duplications of SNCA in PD have also
been found, with even later onset (Chartier-Harlin et
al. 2004; Ibanez et al. 2004). Moreover, the toxicity of
overexpressed wild-type SNCA has been anticipated in
a Drosophila melanogaster model (Feany and Bender
2000) and rodent models (Maries et al. 2003). These
observations emphasize the importance of a-synuclein
levels in PD by showing that elevated levels of wild-type
a-synuclein are sufficient to cause neuronal dysfunction
and disease. Although efforts to identify mutations or
copy-number changes in the SNCA gene in the more
common sporadic forms of PD have failed (Golbe 1999;
Johnson et al. 2004), the importance of a-synuclein in
sporadic PD was re-enforced by the identification of the
protein as a major component of Lewy bodies and Lewy
neurites, the pathological hallmark of PD, in patients
with PD who had no mutation in the SNCA gene (Spil-
lantini et al. 1997). These findings suggest that even
subtle variation in expression of SNCA might play a role
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in the pathogenesis of the disease in those patients who
do not express a mutated protein or have an increase in
gene copy number.
NACP-Rep1 is a polymorphic complex repeat site lo-
cated ∼10 kb upstream of the translational start of SNCA
(Xia et al. 1996; Touchman et al. 2001). The basic se-
quence of NACP-Rep1 is (TC)x(T)2(TC)y(TA)z(CA)w. The
repeat is of interest because several association studies
have shown that certain alleles of NACP-Rep1 may con-
fer an increased risk of sporadic PD in white (Kruger
et al. 1999; Tan et al. 2000; Farrer et al. 2001) and
Asian (Mizuta et al. 2002; Tan et al. 2003; Tan et al.
2004) populations, although other studies have failed
to replicate these findings (Parsian et al. 1998; Izumi et
al. 2001; Khan et al. 2001; Spadafora et al. 2003; Tan
et al. 2003). Previously, we attempted to determine if
the genetic-association studies correlated with biologi-
cal function. Using the luciferase reporter assay system
for promoter activity, we examined the 10-kb region
located upstream of the SNCA gene, including the
NACP-Rep1 repeat, in SH-SY5Y cells (Chiba-Falek and
Nussbaum 2001). We showed that two segments, a few
hundred base pairs in length, flanking the NACP-Rep1
acted in an additive manner to increase promoter func-
tion, whereas the NACP-Rep1 itself was shown to have
a negative effect on expression (Chiba-Falek and Nuss-
baum 2001). In addition, we showed that, in SH-SY5Y
cells, different alleles had a significant effect on expres-
sion levels over a nearly threefold range (Chiba-Falek
and Nussbaum 2001; Chiba-Falek et al. 2003). The
mechanism by which the polymorphic NACP-Rep1 el-
ement affects transcriptional activity of the SNCA pro-
moter remains unknown.
We set out to find proteins that interact with NACP-
Rep1 and thereby mediate the effect of the repeat on
the activity of the SNCA upstream promoter/enhancer.
Here we demonstrate that the DNA-binding protein
PARP-1 interacts with the polymorphic NACP-Rep1 el-
ement and contributes to the transcriptional regulation
of SNCA expression.
Material and Methods
SH-SY5Y Cell Culture and Nuclear Protein Extract
SH-SY5Y, a human neuroblastoma cell line (American
Type Culture Collection), was grown in DMEM/F-12 1:
1 medium, supplemented with 10% fetal bovine serum,
2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Cells were maintained at 37C in a hu-
midified 5% CO2 incubator. Nuclear extracts from this
cell line were prepared as described elsewhere (Dignam
et al. 1983).
Oligonucleotides and Electrophoretic Mobility Shift
Assays
NACP-Rep1 oligonucleotide and a control oligo-
nucleotide (SNCA exon 4) and their matched reverse
oligonucleotides were synthesized chemically (Operon),
as follows: NACP-oligo, TCTCTCTCTCTCTCTCTC-
TCTTTCTCTCTCTCTCTCTCTCTCTATATATATA-
TATATACACACACACACACACACACACA; NACP-
oligo-r, TGTGTGTGTGTGTGTGTGTGTGTATATA-
TATATATATAGAGAGAGAGAGAGAGAGAGAAA-
GAGAGAGAGAGAGAGAGAGA; control-oligo, GA-
GAAGACCAAAGAGCAAGTGACAAATGTTGGAG-
GAGCAGTGGTGACGGGTGTGACAGCAGTAGCC-
CAGAAGACAGTGGA; control-oligo-r, TCCACTGT-
CTTCTGGGCTACTGCTGTCACACCCGTCACCAC-
TGCTCCTCCAACATTTGTCACTTGCTCTTTGGTC-
TTCTC.
Each single-strand (ss) oligonucleotide (NACP and
control) was mixed with the matched reverse ss-oligo-
nucleotide in a molar ratio of 1:1 in TEN-buffer, was
heated to 95C for 10 min, and was slowly cooled (1C
per min) to 15C, to allow a perfect annealing. NACP-
Rep1 and control double stranded (ds) oligonucleotides
were 3′ end-labeled with digoxigenin-11-ddUTP (DIG).
DIG-labeled NACP-Rep1 and control ds-oligonucleo-
tides were used in electrophoretic mobility shift assays
(EMSAs) performed with the DIG Gel Shift kit (Roche)
in accordance with the manufacturer’s instructions. In
brief, DIG-labeled NACP-Rep1 and control ds-oligo-
nucleotides were incubated with SH-SY5Y nuclear ex-
tract or a purified PARP-1 protein (s-recombinant hu-
man wild-type PARP-1, expressed as 6-histidine–tagged
fusion protein in E. coli and purified to 195% homo-
geneity [Smulson et al. 1998], a kind gift from A.
Spoonde) at 25C for 15 min in the presence of poly[d(I-
C)]. For the supershift analysis, 4 ml of monoclonal
anti-PARP-1 antibody (PharMingen) was added to the
SH-SY5Y nuclear extract or the purified PARP-1 and
incubated on ice for 30 min prior to the addition of the
DIG-labeled ds-oligonucleotides. Following the binding
reaction, the mixtures were subjected to electrophoresis
on Novex Retardation Gel (6% polyacrylamide) (Invi-
trogen) and electroblotted to a positively charged nylon
membrane (Roche). The blots were visualized by an en-
zyme immunoassay using anti-digoxigenin-AP, Fab frag-
ments, and the chemiluminescent substrate CSPD (Tro-
pix) and subsequently were exposed to x-ray films.
DNA-Affinity Purification of NACP-Rep1-Binding
Proteins
The protein(s) binding to the NACP-Rep1 DNA ele-
ment were purified using a DNA-Binding Protein Pu-
rification Kit (Roche) in accordance with the manu-
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facturer’s instructions. In brief, NACP-Rep1 ds-oligo-
nucleotide was ligated to a tethered 16-mer ds-oligo-
nucleotide which was 3′ end labeled with biotin at one
site and coupled to streptavidin magnetic particles. SH-
SY5Y nuclear extract (100 mg) was applied to the
DNA–magnetic particle complex, and the binding re-
action was performed at 25C for 30 min in protein-
binding buffer (20 mM Hepes, 1 mM EDTA, 10 mM
(NH4)2SO4, 1 mM DTT, 0.2% Tween 20, 30 mM KCl).
Nonspecific DNA binding was inhibited by the addition
of poly[d(CI)] and [d(AT)]. Subsequently, the bound pro-
tein(s) were separated from the supernatant by use of a
magnetic separator and three washing steps with the
protein-binding buffer. Next, the DNA-binding–pro-
tein(s) mixture was eluted from the magnetic particles
by use of a high-ionic-strength buffer (20 mM Hepes, 1
mM EDTA, 10 mM (NH4)2SO4, 1 mM DTT, 0.2%
Tween 20, and 2 M KCl), followed by dialysis to remove
the high salt concentration. The purified proteins were
run on 4%–20% Novex SDS PAGE gel (Invitrogen) and
the gel was Commassie stained using GelCode Blue
staining reagent (PIERCE).
In Situ Digestion of Proteins in SDS-PAGE Gels
Commassie-stained gel bands were excised with a
clean razor blade and subjected to in situ enzymatic di-
gestion in accordance with a modified version of a stan-
dard protocol (Stone and Williams 1993). In brief, gel
bands were placed in 0.5 ml Eppendorf tubes and de-
stained by the addition of 0.5 ml 50% MeOH:100 mM
NH4HCO3 (1:1) for 1 h. The supernatant was decanted
and discarded. Gel bands were then washed with 0.5 ml
100 mM NH4HCO3 (1:1) for 1 h, followed by 0.5 ml
50% CH3 CN:100 mM NH4HCO3 (1:1) for 1 h. Gel
bands were cut into two or three pieces and then were
washed with 150 mL of neat CH3CN for 15 min to cause
the gel pieces to shrink. The gel pieces were rehydrated
by the addition of 10 mL 100 mM NH4HCO3 containing
10 ng/mL sequencing grade trypsin. Digestion was al-
lowed to proceed overnight at room temperature. Pep-
tides were extracted from the gel pieces by the addition
of an equal volume of 50% CH3CN, 1% HCO2H and
sonication for 30 min. The extraction procedure was
repeated using 80% CH3CN, 1% HCO2H. The pooled
supernatants were dried in a vacuum centrifuge and re-
suspended in 10 mL 5% CH3CN, 1% HCO2H.
LC-MS/MS
The automated HPLC system used was composed of
LC-VP series liquid chromatograph components, in-
cluding three LC-10ADVP solvent delivery pumps, a
DGU-14A online degasser, an SIL-10ADVP autosampler,
an SCL-10AVP system controller, and an FCV-12AH
two-position six-port switching valve (Shimadzu Cor-
poration), with a 0.5 # 2 mm RP trapping column (Pep-
tide CapTrap; Michrom BioResource) mounted on the
FCV-12AH switching valve. Sample solutions were in-
jected using the SIL-10AD autosampler. Mobile phase
A for sample loading was pumped at 50 mL/min, and,
after a 3-min loading and trapping period, the position
of the switching valve was changed to an analysis po-
sition to elute the trapped peptides onto a 0.3 # 100
mm C18 RP column (BetaBasic-18, 0.3 # 100 mm, 5
mm particle size [Thermo Hypersil-Keystone]), operating
at a 10 mL/min flow rate. RP mobile phase A and sample
loading buffer was CH3CN:H2O:HCO2H p 5:95:0.1
(v:v:v) and RP mobile phase B, CH3CN:H2O:HCO2H
p 80:20:0.1. The chromatograph was developed using
a linear gradient from 5% to 65% B in 40 min. The
entire chromatographic effluent was introduced into the
ESI ion source of an LCQ ion trap mass spectrometer
(ThermoFinnigan).
The LCQ was operated in positive ion mode with
dynamic exclusion set to repeat count 2, repeat duration
0.5 min, exclusion duration 1 min, exclusion mass width
3 atomic mass units (amu). Spectra were acquired in a
data-dependent manner, with the top three most intense
ions in the MS scan selected for MS/MS—that is, iter-
ative collection of a survey scan (a full-scan mass spec-
trum from 400 to 1800 m/z [mass/charge ratio]), fol-
lowed by MS/MS of the three most abundant ions
detected in the previous survey scan. Raw data were
submitted to the Mascot cluster maintained by the Cen-
ter for Information Technology of the National Institutes
of Health.
Chromatin Immunoprecipitation (ChIP) and PCR
Analysis
For each ChIP reaction, 1 # 107 SH-SY5Y cells were
fixed by adding formaldehyde to a final concentration
of 1% directly to growth media at 37C for 7 min. The
crosslinking reaction was quenched with glycine at a
final concentration of 0.125 M. Cells were washed with
ice-cold PBS, were lysed in lysis buffer 1 (0.25% Triton
X-100, 0.5 mM EGTA, 1 mM EDTA, 10 mM Tris-HCl
pH 8 and an EDTA-free tablet of protease inhibitor
cocktail [Roche]) for 10 min, rotating at 4C. Nuclei
were pelleted at low speed; were lysed in lysis buffer 2
(200 mM NaCl, 0.5 mM EGTA, 1 mM EDTA, 10 mM
Tris-HCl pH 8 and an EDTA-free tablet of protease in-
hibitor cocktail [Roche]) for 10 min, rotating at 4C;
and were diluted to 5 ml in dilution buffer (1 mM EDTA,
10 mM Tris-HCl pH 8, 0.5 mM EGTA, and an EDTA-
free tablet of protease inhibitor cocktail [Roche]). Chro-
matin was sonicated to ∼500-bp fragments and was cen-
trifuged at 12,000 rpm for 10 min at 4C to remove
debris. The chromatin sample was removed (total ∼4 ml
in dilution buffer) and was split into aliquots. Nonspe-
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cific background was precleared with 20 ml of protein
A agarose beads (Amersham) for 8 h at 4C. The chro-
matin supernatant was aliquoted and either 5 ml of rabbit
polyclonal anti-PARP-1 antibody (Roche), rabbit poly-
clonal IgG (nonspecific control), or no antibody (the
“No Antibody” sample) were added to each aliquot and
incubated overnight at 4C with rotation. The protein
A agarose beads were blocked with 0.5 mg/ml acetylated
BSA (Promega) and 23 mg/ml yeast DNA for 11 h at
4C. Before immunocomplexes were collected with the
blocked beads, a portion (10%) from the “No Anti-
body” sample was set aside to measure input DNA. The
immunocomplexes were precipitated with preblocked
protein A agarose beads for 3 h at 4C. Beads were
washed four times each with high-salt RIPA buffer
(0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycho-
late, 10 mM Tris pH 8, 500 mM NaCl, and an EDTA-
free tablet of protease inhibitor cocktail [Roche]), once
each with LiCl wash buffer (0.25 M LiCl, 0.5% Nonidet
P-40, 0.5% sodium deoxycholate, 1 mM EDTA, 10 mM
Tris pH 8.0), and then twice with TE buffer. Pellets were
resuspended in 150 ml prewarmed elution buffer (1%
SDS, 10 mM EDTA, 50 mM Tris pH 8.0) and were
rotated at 65C for 15 min. Samples were centrifuged
and eluates removed. Input DNA (10% of total sample
previously set aside) was diluted to 150 ml in elution
buffer, and all samples were diluted to a final volume of
300 ml in double deionized water. Cross-links were re-
versed in all samples, and proteins were removed with
the addition of 500 mg/ml proteinase K and incubation
at 37C for 8 h, followed by overnight at 65C. Samples
were extracted with 1:1 phenol/chloroform/isoamyl-al-
cohol and were precipitated in cold ethanol with 33 ml
of 3 M NaAcetate and 20 mg glycogen at 20C for 2
h. Samples were washed with 70% ethanol and resus-
pended in ultrapure water. DNA enrichment was se-
miquantified using PCR. The following primers were
used to detect the enrichment of the NACP-Rep1 DNA
sequence: Rep1 (CCTGGCATATTTGATTGCAA) and
Rep2 (GACTGGCCCAAGATTAACCA). For the detec-
tion of the SNCA 3′ UTR, the following primers were
used: SNCA_3UTRf (TCTGAGGAAGGGTATCAAG-
ACTACGAA) and SNCA_3UTRr (GCACCGAAATG-
CTGAGTGG). For the INPP5B 3′ UTR, the following
primers were used: INPP5B F (TTGATATGACAGAGA-
AGAAGAAGG) and INPP5B R (ATGTCAGTTTTAT-
TATGGTGGATT).
3-Aminobenzamide (3AB) Treatment of SH-SY5Y and
RNA Extraction
SH-SY5Y cells were plated on six-well dishes coated
with poly-L-lysine the day before treatment. DMEM/F-
12 1:1 medium was prepared with 1% DMSO and ei-
ther 0, 3, 10, 15, 30, or 60 mM 3-aminobenzamide
(Sigma). Medium containing different concentrations of
3-AB was added in duplicate to six pairs of cell cultures
and was incubated for 48 h. Then, the cells were washed
with phosphate buffered saline, and total RNA was ex-
tracted using TRIzol reagent (Invitrogen).
cDNA Synthesis and Real-Time PCR
RNA concentration was determined spectrophoto-
metrically at 260 mm and cDNA was synthesized using
MultiScribe RT enzyme (Applied Biosystems) and the
following conditions: 10 min at 25C and 120 min at
37C. Triplicates of each sample were assayed in a rel-
ative quantitative PCR for analysis of the level of SNCA
message, with GAPDH message as an internal reference,
by use of the ABI 7000. Each cDNA (10 ng) was am-
plified in quadruplicate using TaqMan Universal PCR
master mix reagent (Applied Biosystems) under the fol-
lowing conditions: 2 min at 50C and 10 min at 95C,
followed by 40 cycles of 15 s at 95C and 1 min at 60C.
The target SNCA cDNA was amplified using ABI MGB
probe and primer set assay ID Hs00240907_m1, nor-
malized to a GAPDH RNA control (ABI MGB probe
and primer set assay ID Hs00999905_m1) (Applied
Biosystems). Data were analyzed with a threshold set in
the linear range of amplification. The cycle number at
which any particular sample crossed that threshold
(Ct) was then used to determine fold difference. Fold
difference was calculated using the 2DDCt method;
;DCt p [Ct(SNCA  Ct(GAPD)] DDCt p [DCt(sample
. Standards3AB treated)]  [DCt(reference no 3AB)]
curves for each assay using SH-SY5Y RNA samples in-
dicated that the assays were valid while the slope of the
relative efficiency plot for SNCA and GAPDH validated
the DD method (fig. 4A).
Luciferase Reporter Constructs and Transfection
The construction of the pASP plasmid—carrying the
10.7-kb upstream SNCA gene, including the NACP-
Rep1 site—and of the pASP-DNACP, in which the
NACP-Rep1 site was deleted, has been described else-
where (Chiba-Falek and Nussbaum 2001). 1 # 106 SH-
SY5Y cells were plated onto each well of a six-well dish
coated with poly-L-Lysine the day before transfection.
For each experiment involving cotransfection into SH-
SY5Y cells, 2 mg of pASP or pASP-DNACP or 660 ng
of pGL 3-Basic were mixed with 10 ng of the reference
plasmid, pRL-SV40 (harboring the SV40 early enhancer/
promoter region upstream of Renilla luciferase), and co-
transfected using the FuGENE 6 Transfection Reagent
(Roche), in accordance with the manufacturer’s instruc-
tions. Seven hours after transfection, the medium was
replaced with DMEM/F-12, containing either 30 mM
3AB/1% DMSO or 1% DMSO alone. Cells were in-
cubated at 37C for 48 h before harvesting.
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Figure 1 NACP-Rep1 binds protein/s from nuclear SH-SY5Y
extracts. EMSAs were performed with DIG-labeled double-stranded
80 bp oligo including the entire NACP-Rep1 sequence. Lane 1 shows
the DIG-NACP-Rep1 only. SH-SY5Y nuclear extract was used in the
binding assay (lanes 2 and 3). Unlabeled ds-NACP-Rep1 oligo was
used as the specific competitor (lane 3). Unlabeled poly[dCI] and
poly[d(AT)] were used in all lanes as a nonspecific competitor to avoid
nonspecific DNA-binding. The plus () sign indicates what is included
in each reaction while a minus sign () indicates what is excluded
from the reaction. The number in the upper panel indicates the lane
number. A bracket indicates the proteins-NACP-Rep1 complex. The
lower smear, designated by an asterisk (*), indicates the DIG-NACP-
Rep1.
For each experiment, three wells were independently
transfected, in parallel with three individually prepared
aliquots of transfection reaction, and the results from all
three replicates were averaged. Each triplicate experi-
ment was repeated twice on separate days.
Luciferase Assay
SH-SY5Y cells were washed and lysed in 200 ml of
Passive Lysis Buffer (Promega). Firefly luciferase and
Renilla luciferase activities were measured with 10 ml
and 20 ml of SH-SY5Y cell lysate, by use of the Dual-
Luciferase Reporter assay system (Promega) in a lumi-
nometer (EG&G Wallac). “Relative activity” was de-
fined as the ratio of firefly luciferase activity to Renilla
luciferase activity and was calculated by dividing lu-
minescence intensity obtained in the assay for firefly lu-
ciferase by that obtained for Renilla luciferase. “Fold
expression” is defined as the ratio of the relative activity
seen with each 3AB treated or untreated test plasmids
(pASP, pASP-DNACP) to the basal relative activity, and
it was calculated by dividing the average value of relative
activity of each construct to the relative activity of the
pGL 3-Basic plasmid without any insert.
Results
Evidence of Protein Binding to the NACP-Rep1
Element by Electrophoretic Mobility Shift Assay
(EMSA)
Nuclear extract was prepared from the neuroblastoma
cell line, SH-SY5Y. When a digitonin-labeled, double-
stranded 80-mer corresponding to the NACP-Rep1 re-
peat was incubated with the nuclear extract, broad
bands forming a smear were seen (fig. 1, lane 2) that
were shifted upward relative to what we observed in the
absence of nuclear extract (fig. 1, lane 1). The upward
shift was resistant to the nonspecific competitors, an ex-
cess of unlabeled homopolymers poly[d(CI)] and [d(AT)]
(fig. 1, lane 2). This result indicated the existence of SH-
SY5Y nuclear proteins with binding activity towards the
NACP-Rep1 DNA element. After the addition to the
reaction of a 125-fold excess, relative to the DIG-NACP-
Rep1, of unlabeled NACP-Rep1, the upwardly shifted
band was markedly reduced (fig. 1, lane 3). This result
suggested that the protein complexes had specificity for
the NACP-Rep1 sequence. The appearance of multiple
bands in an apparent smear suggests that a heteroge-
neous collection of complete or partial protein com-
plexes were binding to the NACP-Rep1 element.
Isolation and Identification of Proteins that Binds to
NACP-Rep1
Next, we aimed to identify the NACP-Rep1–binding
proteins. NACP-Rep1 ds-oligo was coupled to magnetic
particles and used to purify proteins that bind to the
NACP-Rep1 sequence from the SH-SY5Y nuclear ex-
tract. The purified proteins were subjected to SDS-PAGE
and unique bands were visualized by Commassie stain-
ing, were cut out of the gel, and were identified by mass
spectroscopy (fig. 2A). One of the identified proteins,
which migrated at ∼120 kDa in the gel, was poly (ADP-
ribose) transferase/polymerase-1 (PARP-1) (fig. 2B). Its
identification was based on three peptides with the high-
est score (178) among the other identified proteins (data
not shown).
PARP-1 Binds Specifically to NACP-Rep1 DNA
Sequence
To confirm the binding of PARP-1 to NACP-Rep1,
two approaches were taken: EMSA with purified PARP-
1 protein (fig. 3A) and chromatin immunoprecipitation
Figure 2 Identification of PARP-1 as NACP-Rep1 binding protein. A, Commassie stained gel of the NACP-Rep1 binding proteins that
were purified from SH-SY5Y nuclear extract. The arrow indicates the 120-kDa protein’s band that was used for mass spectrometry identification.
B, Mascot results of the mass spectrometry identification of the 120-kDa band. PARP-1 was identified by three peptides with the highest score
value (178).
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Figure 3 PARP-1 binds to the NACP-Rep1 sequence. A, EMSAs were performed with DIG-labeled double-stranded 80-bp oligo including
the entire NACP-Rep1 sequence. Lane 1 shows the DIG-NACP-Rep1 only. Purified human PARP-1 was used in the binding assay. Anti-PARP-
1 antibody was used for the super shift reaction. Unlabeled ds-NACP-Rep1 oligo was used as the specific competitor, and unlabeled ds-SNCA-
exon 4 oligo was used as the unspecific competitor. The plus sign () indicates what is included in each reaction, whereas a minus sign ()
indicates what is excluded from the reaction. The number in the upper panel is the lane number. Close arrow indicates the PARP-1-NACP-
Rep1 complex (shifted band). Open arrow indicates the PARP-1-antibody-NACP-Rep1 complex (super-shift band). B, ChIPs were carried out
using anti-PARP-1 antibody and IgG antibody. The input control represents the whole DNA of SH-SY5Y cells. Following the ChIP reactions,
a PCR analysis was performed using three different sets of primers. Amplification around the NACP-Rep1 region, control amplifications of the
SNCA 3′ UTR and the Inpp5b gene. The yeast DNA and no DNA control reactions for background failed to amplify. The arrow indicates the
PCR product of the NACP-Rep1 region (270 bp). The unblackened arrowhead indicates the PCR product of the SNCA 3′ UTR (215 bp), and
the blackened arrowhead indicates the PCR product of Inpp5b (284 bp).
(ChIP) (fig. 3B). The in vitro EMSA analysis confirmed
both the binding of PARP-1 to NACP-Rep1 and its spec-
ificity. In the first lane, the reaction includes the DIG-
NACP-Rep1 only. Upon incubation with purified PARP-
1, a shifted band appeared (fig. 3A, lane 2) that was
competed off by unlabeled NACP-Rep1 ds-oligo (fig.
3A, lane 3). Incubation with anti-PARP antibody, prior
to its addition to the DNA-protein–binding reaction, re-
sulted in the appearance of a supershifted band (fig. 3A,
lane 4). The supershifted band was competed off by
unlabeled NACP-Rep1 oligo (fig. 3A, lane 5) but not by
a nonspecific DNA fragment (a sequence from exon 4
of SNCA gene) ds-oligo (fig. 3A, lane 6). A control re-
action of DIG-NACP-Rep1 with the anti-PARP antibody
alone led to no shifted bands (fig. 3A, lane 7). We would
like to note that, to further confirm the specificity of
PARP-1 binding to the NACP-Rep1 sequence, we also
duplicated the set of EMSA reaction presented above,
except for reversing the DIG-labeled oligo and the non-
specific competitor (SNCA exon 4) sequences. Thus, the
DIG-labeled ds-oligo, as well as the specific competitor,
was the control 80-mer sequence of SNCA exon 4,
whereas the nonspecific competitor was the NACP-Rep1
ds-oligo. Upon incubation with purified PARP-1 or
PARP-1 preincubated with anti-PARP, neither the shifted
nor supershifted bands was detected (data not shown).
The above results demonstrate that PARP-1 binds to the
NACP-Rep1 sequence in a specific manner under in vitro
conditions.
ChIP allowed a further in vivo confirmation of the
specific binding of PARP-1 to NACP-Rep1 (fig. 3B). In
the ChIP assay, the SH-SY5Y cells were fixed, thus cross-
linking the DNA-binding proteins to the DNA. Subse-
quent chromatin extraction and immunoprecipitation
(IP) with PARP-1 antibody, followed by reversal of the
cross linking and DNA purification, gave a DNA frac-
tion enriched for DNA sequences that bind PARP-1. We
assayed this fraction for enrichment for the NACP-Rep1
DNA sequence by PCR, with primers flanking the
NACP-Rep1 sequence. PCR amplification with NACP-
Rep1 specific primers revealed an amplified band when
using as template the DNA sample of the ChIP reaction
in which anti-PARP antibody was used for IP (fig. 3B).
PCR of the region flanking the SNCA 3′ UTR was per-
formed on this same ChIP fraction (fig. 3B) and resulted
in no amplification (fig. 3B). Primers flanking the 3′ UTR
of a completely unrelated gene, INPP5B, were also used
as a comparative control and showed no PCR product
with this DNA sample (fig. 3B). There was no ampli-
fication of NACP-Rep1 in control ChIP reactions in
which no antibody was used (data not shown), or an
anti-IgG was used for IP (fig. 3B), or Saccharomyces
cerevisiae DNA (fig. 3B) was used as the DNA blocking
agent. These control samples also failed to show am-
plification of SNCA 3′ UTR and Inpp5b, as expected
(fig. 3B). As a positive control for the PCR itself, we
used the supernatant left after a mock ChIP reaction in
which no antibody was used, which we expected would
represent the total DNA of the SH-SY5Y cells. This sam-
ple of input DNA as template led to amplification of
NACP-Rep1 region and validated the PCR assay of the
NACP-Rep1 region (fig. 3B). These results indicate that
the NACP-Rep1 DNA region was specifically enriched
in the DNA sample derived from the PARP-antibody
ChIP reaction, implying that PARP-1 binds to NACP-
Rep1 element in vivo and that the binding of PARP-1
to NACP-Rep1 sequence is specific.
Inhibition of the Enzymatic Activity of PARP-1 Elevates
SNCA Levels
3-Aminobenzamide (3-AB) is known for its ability to
inhibit the PARP-1 catalytic domain. 3-AB (3–60 mM)
was used to inhibit PARP-1 activity in SH-SY5Y cells,
to study the effect on endogenous steady-state SNCA
mRNA levels. Cells were treated with six different con-
centrations of 3-AB (0, 3, 10, 15, 30, and 60 mM) for
48 h, after which RNA was extracted and levels of en-
dogenous SNCA mRNA were analyzed by real-time
PCR (see assay validation in fig. 4A). In general, PARP-
1 inhibition resulted in an increase in the levels of SNCA
mRNA in a dose-responsive manner (fig. 4B). A slight
(1.4-fold) increase in SNCA mRNA was detected on
treatment with 3-AB at a concentration as low as 3 mM
(fig. 4B). Doses of 3-AB from 0 to 30 mM led to a
significant increase in the levels of SNCA mRNA, up to
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Figure 4 Real-time analysis of SNCA mRNA levels in SH-SY5Y cell after 3-AB treatment. A, Validation curve of the DD real-time assay
for relative quantization of SNCA mRNA relatively to GAPDH mRNA. A relative efficiency plot of SNCA and GAPDH was formed by plotting
the log input amount (ng of total RNA) versus the DCt [Ct(SNCA)Ct(GAPDH)]. The slop is , which indicates the validation of0.0638 ! 0.1
the DDCt calculation in the range of 1–100 ng RNA. B, Cells were treated with 3AB in different concentrations (0, 3, 10, 15, 30, and 60 mM),
and the relative levels of SNCA mRNA to GAPDH mRNA were assessed by real-time PCR and were analyzed by the DD method. The 3-AB
concentration (mM) is indicated on the X-axis, and the fold increase of SNCA mRNA is indicated on the Y-axis. Each data point represents
the average of three repeats.
3.5-fold, which appeared to be linear (fig. 4B). However,
further increase in 3-AB concentration from 30 to 60
mM produced only a slight additional increase in SNCA
mRNA, from 3.5 to 3.7 fold, suggesting the response
had reached a plateau (fig. 4B). These results indicate
that inhibition of the PARP-1 catalytic domain was as-
sociated with in an increase in steady-state SNCA
mRNA level of ∼3.7 fold over untreated cells.
Inhibition of the Enzymatic Activity of PARP-1
Increases the Activity of SNCA Promoter/Enhancer
Region
Our previous studies showed the importance of the
region containing the human NACP-Rep1 repeat in the
transcriptional regulation of human SNCA gene ex-
pression (Chiba-Falek and Nussbaum 2001; Touchman
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et al. 2001). To investigate whether alterations in tran-
scriptional activity of the SNCA gene contributed to the
increase in steady-state SNCA mRNA levels induced by
3-AB treatment, we examined the effect of 3-AB on the
activity of luciferase driven by the 10.7-kb region up-
stream of SNCA translational start (Touchman et al.
2001) using constructs that either contained the NACP-
Rep1 sequence (pASP) or were deleted for the sequence
(pASP-DNACP) (Chiba-Falek and Nussbaum 2001).
These constructs were transfected into the neuroblas-
toma cell line SH-SY5Y and treated with 3-AB or left
untreated. Each plasmid was cotransfected with pRL-
SV40. Eight hours after transfection, half of the wells
were exposed to 30 mM of 3-AB, and half remained
untreated for 48 h. Subsequently, cells were harvested,
protein extracts were prepared, and the levels of firefly
and Renilla luciferase expression were measured. As a
control for luciferase basal expression, we also cotrans-
fected the commercial promoter-less plasmid, pGL 3-
Basic, with the pRL-SV40 plasmid. For each cotrans-
fection experiment, the relative activity of luciferase to
the Renilla enzyme was calculated, to eliminate the effect
of transfection efficiency and cell number (see the “Ma-
terial and Methods” section).
The full-length plasmid, pASP demonstrated a ∼2.7-
fold lower luciferase activity in SH-SY5Y as compared
with the deleted plasmid, pASP-DNACP; 3.1-fold ex-
pression compared with 8.4-fold expression, respectively
(fig. 5A). This result confirmed our previous observa-
tions that the NACP-Rep1 DNA sequence acts as a tran-
scription-repressor element (Chiba-Falek and Nussbaum
2001). Upon treatment with 3-AB, the full-length con-
struct, pASP, gave a twofold increase in the expression
of the luciferase, relative to the untreated cells (fig. 5B).
This result indicates that PARP-1 inhibition led to higher
promoter activity in SH-SY5Y cells transfected with the
full-length construct (pASP). Thus, PARP-1 may be one
element of the transcriptional machinery that acts on
the NACP-Rep1 element to down regulate SNCA tran-
scription. In contrast, treatment with 3-AB of SH-SY5Y
cells transfected with the deleted NACP-Rep1 construct
showed a decrease (1.7 fold) in luciferase activity (fig.
5B). Thus, PARP-1 inhibition resulted in lower promoter
activity for the deleted construct (pASP-DNACP). Thus,
inhibition of PARP-1 catalytic domain by 3-AB treat-
ment had the opposite effect on luciferase expression
driven by pASP and by pASP-DNACP, with pASP show-
ing an overall ∼4-fold higher elevated expression, com-
pared with pASP-DNACP (fig. 5B). These results illus-
trate that active PARP-1 could have an overall repressing
effect on SNCA transcription via its interaction with
NACP-Rep1 but other elements may reside within the
SNCA promoter/enhancer region, through which PARP-
1 acts to increase SNCA transcription, either directly,
through DNA binding, or indirectly, through an effect
on other transcription factors that can affect SNCA
expression.
Discussion
One of the more important outstanding questions for
research into the molecular pathogenesis of PD is the
role of a-synuclein in sporadic PD. a-Synuclein may be
involved in PD through altered regulation of a-synuclein
expression, among other possible mechanisms. Although
efforts to identify a-synuclein mutations in sporadic PD
have failed, there is accumulating evidence in both in
vitro systems (Hashimoto et al. 1998) and in vivo models
(Masliah et al. 2000) suggesting that higher expression
levels of this protein are sufficient to cause the disease.
Several studies imply that overexpression of wild-type
a-synuclein can be toxic to cells (Ostrerova et al. 1999)
and that dopaminergic neurons might be particularly
vulnerable to toxicity from a-synuclein overexpression.
More recently, genomic duplication or triplication of the
region containing SNCA has been documented in af-
fected individuals from families with autosomal domi-
nant PD (Singleton et al. 2003; Chartier-Harlin et al.
2004; Ibanez et al. 2004). In the case of the triplication,
four fully functional copies of a-synuclein were associ-
ated with twofold overexpression of a-synuclein mRNA
and protein (Farrer et al. 2004; Miller et al. 2004). This
finding emphasizes the importance of a-synuclein levels
in PD, showing that elevated levels of wild-type a-syn-
uclein are sufficient to cause familial early-onset PD.
Thus, the regulation of a-synuclein expression might
play an important role in the susceptibility to develop
PD more generally.
Several association studies have shown that certain
alleles of the NACP-Rep1 locus may confer an increased
risk of sporadic PD (Kruger et al. 1999; Tan et al. 2000,
2003, 2004; Farrer et al. 2001; Mizuta et al. 2002).
Our previous study suggested a model in which the
polymorphic NACP-Rep1 element is involved in the reg-
ulation of SNCA expression, but exactly how the repeat
can modulate the expression level is still unknown. As
a first step towards understanding the role of NACP-
Rep1 in the control of SNCA expression, we identified
a protein, PARP-1, that binds NACP-Rep1 and found
it to be involved in the regulation of SNCA expression
Poly (ADP-ribose) polymerase-1 (PARP-1) is a 116-
kDa nuclear protein widely known for its DNA-binding
properties (Soldatenkov et al. 2002) and for a unique
enzymatic activity, ADP-ribosylation. PARP-1 can bind
with high affinity in a cooperative manner to different
DNA structures (e.g., cruciform, curved, supercoiled,
crossover, stem-loop, and base unpairing region [BUR],
as well as some specific double-stranded sequences) (Sol-
datenkov et al. 2002; Kraus and Lis 2003). Its enzymatic
activity is to catalyze the covalent attachment of ADP-
Figure 5 Fold expression of luciferase activity derived by full-length and NACP-Rep1–deleted pASP constructs in SH-SY5Y cells before
and after 3-AB treatment. A, Cells were transfected with each construct or pGL 3-Basic. The relative activity for each pASP or pGL 3-Basic
plasmid was calculated by dividing the luminescence intensity of the firefly luciferase by that of the cotransfected Renilla luciferase in each
independent aliquot of cells and then averaging the three relative luciferase activities seen. The fold expression for pASP and pASP-DNACP
was then determined by dividing the average relative activity of each construct to that of the average obtained with pGL 3-Basic. B, The ratio
of fold expression of luciferase activity derived by the full-length pASP and pASP-DNACP in SH-SY5Y cells upon 3-AB treatment. Cells were
cotransfected with each of the two constructs (full-length and NACP-Rep1 deletion) or pGL 3-Basic and pRL. In each experiment for each
construct, three well were untreated and three were treated with 30 mM 3-AB for 48 h. For each construct, two to three independent experiments
were performed. The relative activity for each pASP, with and without 3-AB treatment or pGL 3-Basic plasmid, was calculated by dividing the
luminescence intensity of the firefly luciferase by that of the cotransfected Renilla luciferase in each independent aliquot of cells and then
averaging the three relative luciferase activities seen. The fold expression for each pASP with and without 3-AB treatment was then determined
by dividing the average relative activity of each construct to that of the average obtained with pGL 3-Basic. Then, the ratio of the fold expression
for each of the 3-AB treated cells transfected with each construct (pASP and pASP-DNACP) relative to the untreated cells transfected with the
same construct was determined. The average of the ratios of two to three independent experiments performed on separate days was calculated.
A bar in the positive scale of the Y-axis indicates an increase in luciferase activity upon 3-AB treatment, and a bar in the negative scale of the
Y-axis indicates a decrease in luciferase activity upon 3-AB treatment.
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ribose units from its substrate b-NAD to several
nuclear-acceptor proteins, including itself (D’Amours
et al. 1999). Initial studies implicated this enzyme in
many crucial biological functions, including DNA re-
pair, replication, recombination, apoptosis, and cancer
(D’Amours et al. 1999; Virag and Szabo 2002). A role
for PARP-1 in transcriptional regulation of specific
genes has also been demonstrated using a variety of
experimental approaches (Kraus and Lis 2003). PARP-
1 was identified as a constituent of the positive cofactor-
1 complex, which is essential for the activity of several
transcription factors (Guermah et al. 1998). The role
of PARP-1 in transcription is well established by the
demonstration by several groups of its potent effect on
some transcription factors (Whitacre et al. 1995; Nie et
al. 1998; Butler and Ordahl 1999; Kannan et al. 1999;
Oliver et al. 1999; Anderson et al. 2000; Cervellera and
Sala 2000; Hassa and Hottiger 2002; Virag and Szabo
2002). Gene-expression studies using microarrays in-
dicated the effect of PARP-1 on the expression of 190
genes (Simbulan-Rosenthal et al. 2000).
Two mechanisms, at least, have been suggested for
how PARP-1 might be involved in transcriptional reg-
ulation: (1) modifying histones to alter chromatin struc-
ture and (2) participating in forming promoter/enhancer
binding complexes, in conjunction with other DNA-
binding factors and coactivators (Kraus and Lis 2003).
There is evidence that PARP-1 can act as a transcription
activator (Anderson et al. 2000; Cervellera and Sala
2000; Hassa and Hottiger 2002), but other data show
that PARP-1 may repress transcription (Butler and Or-
dahl 1999; Miyamoto et al. 1999; Soldatenkov et al.
2002). Recently, PARP-1 was shown to have a distinctly
dualistic role, with opposing effects in AP-2a-mediated
transcriptional regulation. It was demonstrated that
separate regions of PARP-1 interact with AP-2a and
independently control its transcriptional activation;
while PARP-1’s middle region enhances transcription,
its catalytic domain functions to repress transcription
(Li et al. 2004).
In this study, we found, using both in vitro and in
vivo approaches, that PARP-1 interacts with the NACP-
Rep1 site and contributes to the regulation of a-synu-
clein expression. NACP-Rep1 does not contain a known
PARP-1 recognition sequence, and thus the basis of the
recognition of NACP-Rep1 by PARP-1 is not clear. One
can speculate that this repeat sequence might tend to
form certain DNA conformations such as a BUR, a
structure that is recognized by PARP-1. However, we
cannot exclude the possibility that NACP-Rep1 con-
tains a new sequence-specific recognition site of PARP-
1. It is important to note that, when we used a whole
nuclear extract in the EMSA, the labeled DNA was
shifted upward to form a smear, rather than a discrete
band as was seen when purified PARP-1 was used. This
result implies that PARP-1 might be a part of a protein
complex that interacts with NACP-Rep1 and that
PARP-1 is likely to be one of the proteins in the complex
that binds NACP-Rep1 directly.
Our previous and current findings indicate that
NACP-Rep1 functions as a repressor element. In light
of these data, one can speculate that PARP-1 acts as a
transcription repressor of the SNCA gene through its
interaction with NACP-Rep1. Inhibition of PARP-1’s
enzymatic activity with 3-aminobenzamide abrogated
this repressive effect and led to elevated levels of en-
dogenous SNCA mRNA in SH-SY5Y cells. The repres-
sive effect of PARP-1 on SNCA expression and its re-
versal by 3-aminobenzamide appears to be transcrip-
tional, at least in part, as shown by our luciferase re-
porter assays. A number of hypothetical models could
be envisioned for how inhibition of PARP-1’s enzymatic
activity might either directly or indirectly up-regulate
SNCA expression. (1) Enzymatically active PARP-1
might alter chromatin structure at the NACP-Rep1 re-
gion to a transcriptionally inaccessible form of DNA,
while inhibition of the PARP-1 catalytic domain results
in an open DNA conformation and transcriptional up-
regulation. (2) Enzymatically active PARP-1 might re-
cruit transcriptional repressors and/or prevent the bind-
ing and interaction of transcriptional activators while
inhibition of PARP-1 would have the opposite effect
(i.e., to reduce the binding of the repressors or allow
transcriptional activators to bind), leading to up-regu-
lation of expression. Each of these models can act either
via (a) PARP-1’s catalytic property (i.e., ADP-ribosy-
lation) or (b) its DNA-binding property, if enzymatically
active and inactive PARP-1 bind the NACP-Rep1 seg-
ment differently. It should be noted that the effect on
SNCA promoter/enhancer function of inhibiting PARP-
1’s enzymatic activity depends on the NACP-Rep1 se-
quence being present: inhibition of PARP-1 in cells
transfected with the NACP-Rep1 deleted construct re-
sulted in an opposite effect, namely a decrease in SNCA
promoter/enhancer transcriptional activity. This result
may reflect a nonspecific effect of PARP-1 inhibition or
may indicate that other recognition site(s) of PARP-1
may reside along the SNCA promoter/enhancer region
and allow PARP-1 to play a dualistic role in SNCA
transcriptional regulation. If this were the case, the ac-
tual effect of PARP-1 on SNCA transcription could be
the result of a balance between the effect of its inter-
action with NACP-Rep1 and its interaction with other
sites upstream of the start of SNCA transcription.
The mechanism of how PARP-1 might be involved in
transcriptional regulation of SNCA is unclear. Previ-
ously, we demonstrated that the two segments that flank
the NACP-Rep1 appeared responsible, in an additive
manner, for expression, whereas the NACP-Rep1 itself
was shown to have a negative effect on expression
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(Chiba-Falek and Nussbaum 2001). These results sug-
gest a model of two regulatory regions, one located
upstream of the NACP-Rep1 and the other downstream
of the repeat. The transcription factors binding in these
two regions may interact to function in an additive man-
ner, while different alleles of NACP-Rep1 modulate this
interaction to different degrees. PARP-1 binding to the
repeat might contribute to the modulation of this in-
teraction. Exactly how PARP-1 functions in this mod-
ulation is unknown, but it could be altering how effec-
tively or efficiently the transcription factors that bind
upstream and downstream of the repeat can interact,
or it could be modulating the recruitment, binding, and/
or activation of these transcription factors. In the future,
it will be of interest to analyze the variation among the
different NACP-Rep1 alleles, with respect to PARP-1
binding affinity and its effect on the transcriptional reg-
ulation of SNCA.
Our current and previous experiments lend support
to the hypothesis that the NACP-Rep1 microsatellite in
cooperation with its binding protein, PARP-1, have a
physiological function in the regulation of SNCA gene
expression. Thus, one can speculate that polymorphism
at this microsatellite might be involved in sporadic PD
via its effect on the expression of the SNCA gene,
thus contributing, among other factors, to the risk for
disease.
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